This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (40)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Bacterial Infections  • Endophthalmitis  • Articles for Residents  • Infectious Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

Seenu M. Hariprasad, MD; William F. Mieler, MD; Eric R. Holz, MD

Arch Ophthalmol. 2003;121:345-350.

Objective  To investigate the penetration of gatifloxacin, a novel extended-spectrum fourth-generation fluoroquinolone antibiotic, into the vitreous and aqueous humor after oral administration.

Methods  A prospective, nonrandomized study of 24 consecutive patients scheduled for pars plana vitrectomy between September 2001 and May 2002 at the Cullen Eye Institute. Aqueous, vitreous, and serum samples were obtained and analyzed from 24 patients after administration of two 400-mg gatifloxacin tablets taken 12 hours apart before the operation. Assays were performed using high-performance liquid chromatography.

Results  Mean ± SD gatifloxacin concentrations in serum (n = 23), vitreous (n = 23), and aqueous (n = 11) were 5.14 ± 1.36 µg/mL, 1.34 ± 0.34 µg/mL, and 1.08 ± 0.54 µg/mL respectively. Mean ± SD sampling times after oral administration of the second gatifloxacin tablet for serum, vitreous, and aqueous were 3.2 ± 1.0 hours, 4.0 ± 1.0 hours, and 3.9 ± 1.1 hours, respectively. The percentages of serum gatifloxacin concentration achieved in the vitreous and aqueous were 26.17% and 21.02%, respectively. Mean inhibitory vitreous and aqueous MIC₉₀ levels were achieved against many pathogens, including Staphylococcus epidermidis, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes, Propionibacterium acnes, Haemophilus influenzae, Escherichia coli, Bacillus cereus, Proteus mirabilis, and other organisms.

Conclusions  Orally administered gatifloxacin achieves therapeutic levels in the noninflamed human eye, and the activity spectrum appropriately encompass the bacterial species most frequently involved in the various causes of endophthalmitis. Because of its broad-spectrum coverage, low MIC₉₀ levels for the organisms of concern, and good tolerability, gatifloxacin represents a major advance in the prophylaxis or treatment of postoperative, posttraumatic, and bleb-associated bacterial endophthalmitis.

From the Department of Ophthalmology/Cullen Eye Institute, Baylor College of Medicine, Houston, Tex. The authors have no relevant financial interest in this article.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Toward Improving Therapeutic Regimens for Bacillus Endophthalmitis
Wiskur et al.
IOVS 2008;49:1480-1487.
ABSTRACT | FULL TEXT  

In vitro fluoroquinolone resistance in staphylococcal endophthalmitis isolates.
Miller et al.
Arch Ophthalmol 2006;124:479-483.
ABSTRACT | FULL TEXT  

Vitreous and aqueous penetration of orally administered moxifloxacin in humans.
Hariprasad et al.
Arch Ophthalmol 2006;124:178-182.
ABSTRACT | FULL TEXT  

Penetration of moxifloxacin into the human aqueous humour after oral administration
Kampougeris et al.
Br J Ophthalmol 2005;89:628-631.
ABSTRACT | FULL TEXT  

Penetration Pharmacokinetics of Topically Administered 0.5% Moxifloxacin Ophthalmic Solution in Human Aqueous and Vitreous
Hariprasad et al.
Arch Ophthalmol 2005;123:39-44.
ABSTRACT | FULL TEXT  

Vitreous and Aqueous Penetration of Orally Administered Gatifloxacin in Humans
Fuller and Marcus
Arch Ophthalmol 2004;122:1408-1409.
FULL TEXT  

Vitreous and Aqueous Penetration of Orally Administered Gatifloxacin in Humans--Reply
Hariprasad et al.
Arch Ophthalmol 2004;122:1409-1409.
FULL TEXT